Ready-to-use CARDENE® I.V. (nicardipine hydrochloride) for blood pressure reduction in neuroemergencies
Key considerations for choosing an antihypertensive agent in neuroemergencies
CARDENE® I.V. (nicardipine hydrochloride) Premixed Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits.
CARDENE I.V. is not indicated for the treatment or prevention of AIS, ICH, or SAH
CARDENE I.V. achieved rapid BP reduction in patients with AIS, ICH, or SAH, with control maintained over 24 hours3
- 26 patients treated
- 215 mm Hg* initial SBP
- 89% of patients achieved their respective SBP goals within 60 minutes
- ≤1 dose adjustment* needed to reach BP goal
- 1 instance of hypotension
- No rescue therapy required
- Gradual titration of CARDENE® I.V. (nicardipine hydrochloride) was used
30 Minutes* to Achieve Goal BPA prospective, pseudo-randomized study of patients who presented to the ED with primary ICH (n=16), SAH (n=1), or AIS (n=9) receiving CARDENE I.V. for 24 hours. CARDENE I.V. was administered at 5 mg/hr and increased every 15 minutes by 2.5 mg/hr until target SBP range was reached or a maximum of 15 mg/hr was achieved. BP goals were defined using current consensus recommendations. Vital signs (BP and HR) were taken every 15 minutes until goal BP was achieved.3
Did you know?
In AIS, management of hypertension is key in the timing of fibrinolytic therapy?4